- Home
- REAX vs AUTL Comparison
REAX vs AUTL Comparison
Compare REAX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAX
- AUTL
- Stock Information
- Founded
- REAX 2018
- AUTL 2014
- Country
- REAX United States
- AUTL United Kingdom
- Employees
- REAX N/A
- AUTL N/A
- Industry
- REAX
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REAX
- AUTL Health Care
- Exchange
- REAX Nasdaq
- AUTL Nasdaq
- Market Cap
- REAX 1.1B
- AUTL 1.1B
- IPO Year
- REAX N/A
- AUTL 2018
- Fundamental
- Price
- REAX $4.95
- AUTL $3.08
- Analyst Decision
- REAX Strong Buy
- AUTL Strong Buy
- Analyst Count
- REAX 2
- AUTL 2
- Target Price
- REAX $5.25
- AUTL $11.50
- AVG Volume (30 Days)
- REAX 774.1K
- AUTL 2.3M
- Earning Date
- REAX 11-07-2024
- AUTL 11-12-2024
- Dividend Yield
- REAX N/A
- AUTL N/A
- EPS Growth
- REAX N/A
- AUTL N/A
- EPS
- REAX N/A
- AUTL N/A
- Revenue
- REAX $1,095,350,000.00
- AUTL $10,091,000.00
- Revenue This Year
- REAX $77.75
- AUTL $816.67
- Revenue Next Year
- REAX $27.76
- AUTL $374.47
- P/E Ratio
- REAX N/A
- AUTL N/A
- Revenue Growth
- REAX 81.37
- AUTL 82.71
- 52 Week Low
- REAX $1.28
- AUTL $2.94
- 52 Week High
- REAX $6.75
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- REAX 40.26
- AUTL 35.72
- Support Level
- REAX $5.25
- AUTL $3.24
- Resistance Level
- REAX $6.61
- AUTL $4.12
- Average True Range (ATR)
- REAX 0.38
- AUTL 0.37
- MACD
- REAX -0.05
- AUTL -0.09
- Stochastic Oscillator
- REAX 1.19
- AUTL 8.48
About REAX The Real Brokerage Inc.
The Real Brokerage Inc is a technology-powered real estate brokerage firm. It has developed, integrated, and adopted various mobile and desktop-focused technologies to create a comprehensive offering to its agents and to assist Real with its brokerage operations. The group delivers a cloud-based platform to improve efficiencies and empower real estate agents to provide a seamless end-to-end experience for homebuyers and sellers. The company generates its maximum revenue from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.